Αρχική World News FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma World News FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma Από Ogkologos - 27 Οκτωβρίου, 2025 439 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer 15 Μαΐου, 2019 Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... 13 Ιανουαρίου, 2021 Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological... 16 Ιουλίου, 2021 FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma 13 Νοεμβρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... Genetic discovery could guide treatment for aggressive childhood cancer 癌症治疗期间如何保证日常活动的安全和独立执行 Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult...